ES2991062T3 - Composición farmacéutica - Google Patents

Composición farmacéutica Download PDF

Info

Publication number: ES2991062T3
Authority: ES; Spain
Prior art keywords: pharmaceutical composition; granulation method; compound; composition according; pharmaceutically acceptable
Prior art date: 2017-02-15
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Active

Application number

ES18755023T

Other languages

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Taiho Pharmaceutical Co Ltd

Original Assignee

Taiho Pharmaceutical Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2017-02-15

Filing date

2018-02-14

Publication date

2024-12-02

2018-02-14 Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd

2024-12-02 Application granted granted Critical

2024-12-02 Publication of ES2991062T3 publication Critical patent/ES2991062T3/es

Status Active legal-status Critical Current

2038-02-14 Anticipated expiration legal-status Critical

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/04—Nitro compounds

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Inorganic Chemistry (AREA)
Physical Education & Sports Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Molecular Biology (AREA)
Orthopedic Medicine & Surgery (AREA)
Biophysics (AREA)
Rheumatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)

ES18755023T 2017-02-15 2018-02-14 Composición farmacéutica Active ES2991062T3 (es)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
JP2017026203		2017-02-15
PCT/JP2018/005140 WO2018151177A1 (fr)	2017-02-15	2018-02-14	Composition pharmaceutique

Publications (1)

Publication Number	Publication Date
ES2991062T3 true ES2991062T3 (es)	2024-12-02

Family

ID=63169269

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ES18755023T Active ES2991062T3 (es)	2017-02-15	2018-02-14	Composición farmacéutica

Country Status (20)

Country	Link
US (2)	US11110062B2 (fr)
EP (1)	EP3583943B1 (fr)
JP (1)	JP6771594B2 (fr)
KR (2)	KR20210135354A (fr)
CN (2)	CN110312511B (fr)
AU (1)	AU2018222163C1 (fr)
CA (1)	CA3053739C (fr)
DK (1)	DK3583943T3 (fr)
ES (1)	ES2991062T3 (fr)
FI (1)	FI3583943T3 (fr)
HU (1)	HUE068810T2 (fr)
MA (1)	MA47516A (fr)
MX (2)	MX383728B (fr)
MY (1)	MY194278A (fr)
PH (1)	PH12019501873A1 (fr)
PL (1)	PL3583943T3 (fr)
PT (1)	PT3583943T (fr)
SG (1)	SG11201907433TA (fr)
TW (1)	TWI702951B (fr)
WO (1)	WO2018151177A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP3583943B1 (fr)	2017-02-15	2024-09-18	Taiho Pharmaceutical Co., Ltd.	Composition pharmaceutique
MA50251A (fr) *	2017-09-08	2021-06-02	Taiho Pharmaceutical Co Ltd	Agent antitumoral et potentialisateur d'effet antitumoral
AU2019342447B2 (en)	2018-09-18	2025-05-29	Taiho Pharmaceutical Co., Ltd.	Combination therapy of acylthiourea compound and abiraterone
TWI872203B (zh)	2020-02-14	2025-02-11	日商大鵬藥品工業股份有限公司	醯基硫脲化合物的製造方法
WO2022191683A1 (fr)	2021-03-12	2022-09-15	주식회사 엘지에너지솔루션	Ensemble barre omnibus, bloc-batterie comprenant un ensemble barre omnibus, et véhicule comprenant un bloc-batterie
US20230114887A1 (en)	2021-10-12	2023-04-13	Lg Energy Solution, Ltd.	Battery pack and vehicle including the same

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5254541A (en)	1991-11-15	1993-10-19	Merck Frosst Canada, Inc.	(Quinolin-2-ylmethoxy)indole/cyclodextrin complex
CN1154070A (zh) *	1994-05-27	1997-07-09	荷兰发马克有限公司	药物组合物
TWI281915B (en)	1999-12-24	2007-06-01	Kirin Brewery	Quinoline and quinazoline derivatives and drugs containing the same
WO2002032872A1 (fr)	2000-10-20	2002-04-25	Eisai Co., Ltd.	Composes a noyau aromatique azote
AU2002313249B2 (en)	2001-06-22	2008-08-21	Kirin Pharma Kabushiki Kaisha	Quinoline derivative and quinazoline derivate inhibiting self-phosphorylation of hepatocytus proliferator receptor, and medicinal composition containing the same
SE520606C2 (sv)	2001-06-26	2003-07-29	Flir Systems Ab	Förfarande för att åstadkomma en spegelyta, samt spegel med sådan spegelyta
JP2003238592A (ja)	2001-12-13	2003-08-27	Japan Tobacco Inc	組織及び血管の再生のための医薬及びその方法
CN1448053A (zh) *	2003-04-22	2003-10-15	西安敬业生物药物科技有限公司	甲基托布津包络物农药制剂
PT2213661E (pt)	2003-09-26	2011-12-15	Exelixis Inc	Moduladores de c-met e métodos de uso
AU2005217325B2 (en)	2004-02-27	2007-11-29	Eisai R & D Management Co., Ltd.	Novel pyridine derivative and pyrimidine derivative (1)
WO2005105044A1 (fr) *	2004-04-30	2005-11-10	Ranbaxy Laboratories Limited	Procede de fabrication d'un complexe d'inclusion de sulfonylurees presentant une solubilite aqueuse amelioree
WO2005121125A1 (fr)	2004-06-09	2005-12-22	Pfizer Inc.	Composes heteroaryle a liaison ether
US7173031B2 (en)	2004-06-28	2007-02-06	Bristol-Myers Squibb Company	Pyrrolotriazine kinase inhibitors
CN100448053C (zh) *	2004-08-31	2008-12-31	清华大学	含有屏蔽掩膜支撑体的有机电致发光器件及其制备方法
AU2006229343A1 (en)	2005-03-28	2006-10-05	Kirin Pharma Kabushiki Kaisha	Thienopyridine derivative, or quinoline derivative, or quinazoline derivative, having c-Met autophosphorylation inhibiting potency
US20080161305A1 (en)	2005-04-06	2008-07-03	Exelixis, Inc.	C-Met Modulators and Methods of Use
US7728017B2 (en)	2005-11-30	2010-06-01	Vertex Pharmaceuticals Incorporated	Inhibitors of c-Met and uses thereof
AU2008315746A1 (en)	2007-10-25	2009-04-30	Astrazeneca Ab	Pyridine and pyrazine derivatives useful in the treatment of cell proliferative disorders
CN101491240A (zh) *	2008-01-25	2009-07-29	国家农产品保鲜工程技术研究中心（天津）	提高纳他霉素作用效率的方法
BRPI0906576A2 (pt)	2008-01-29	2015-07-07	Eisai R&D Man Co Ltd	Composição farmacêutica, kit, uso de um composto, e, agente terapêutico para câncer
JP2011513427A (ja)	2008-03-06	2011-04-28	ジェネンテック，インコーポレイテッド	ｃ−ｍｅｔ及びＥＧＦＲアンタゴニストの併用療法
CA2720552C (fr)	2008-04-10	2016-06-14	Taiho Pharmaceutical Co., Ltd.	Compose d'acylthiouree ou son sel, et utilisation du compose ou du sel
UY31800A (es)	2008-05-05	2009-11-10	Smithkline Beckman Corp	Metodo de tratamiento de cancer usando un inhibidor de cmet y axl y un inhibidor de erbb
US20110104161A1 (en)	2008-05-14	2011-05-05	Burgess Teresa L	Combinations vegf(r) inhibitors and hepatocyte growth factor (c-met) inhibitors for the treatment of cancer
UY32049A (es)	2008-08-14	2010-03-26	Takeda Pharmaceutical	Inhibidores de cmet
AU2009314072C1 (en) *	2008-11-15	2016-11-10	Melinta Subsidiary Corp.	Antimicrobial compositions
WO2010093789A2 (fr)	2009-02-12	2010-08-19	Arqule, Inc.	Compositions combinatoires et procédés pour le traitement du cancer
CN101926808A (zh)	2009-06-25	2010-12-29	积华药业有限公司	氨基葡萄糖制剂
AU2011269788B2 (en)	2010-02-03	2015-12-10	Incyte Holdings Corporation	Imidazo[1,2-b][1,2,4]triazines as c-Met inhibitors
EA201690998A1 (ru)	2010-05-17	2017-01-30	Инкозен Терапьютикс Пвт. Лтд.	НОВЫЕ СОЕДИНЕНИЯ 3,5-ДИЗАМЕЩЕННОГО-3H-ИМИДАЗО[4,5-b]ПИРИДИНА И 3,5-ДИЗАМЕЩЕННОГО-3H-[1,2,3]ТРИАЗОЛО[4,5-b]ПИРИДИНА КАК МОДУЛЯТОРЫ ПРОТЕИНКИНАЗ
CN102274189A (zh) *	2011-07-21	2011-12-14	瑞普（天津）生物药业有限公司	一种含有癸氧喹酯的干混悬剂组方及其制备方法
TW201322979A (zh)	2011-10-18	2013-06-16	Raqualia Pharma Inc	醫藥組成物
TWI594986B (zh)	2011-12-28	2017-08-11	Taiho Pharmaceutical Co Ltd	Antineoplastic agent effect enhancer
RU2494470C1 (ru)	2012-04-04	2013-09-27	Общество с ограниченной ответственностью "Саентифик Фьючер Менеджмент" (ООО "Саентифик Фьючер Менеджмент")	Способ лечения фиброза легких
HRP20251029T1 (hr)	2013-07-19	2025-10-24	Boehringer Ingelheim Vetmedica Gmbh	Konzervirani eterificirani derivati ciklodekstrina koji sadrže tekući vodeni farmaceutski pripravak
US9149471B2 (en)	2013-09-30	2015-10-06	National University Corporation Tokyo University Of Agriculture And Technology	Therapeutic agent for osteoporosis
EP3572430A3 (fr)	2014-03-05	2020-02-12	Bristol-Myers Squibb Company	Traitement du cancer du rein à l'aide d'une combinaison d'un anticorps anti-pd-1 et d'un autre agent anticancéreux
AU2015358384B2 (en)	2014-12-03	2021-03-04	Auckland Uniservices, Ltd.	Kinase inhibitor prodrug for the treatment of cancer
JP2016196411A (ja)	2015-03-04	2016-11-24	エーザイ・アール・アンド・ディー・マネジメント株式会社	腫瘍治療剤
WO2016140717A1 (fr)	2015-03-04	2016-09-09	Merck Sharp & Dohme Corp.	Association d'un antagoniste de pd-1 et d'un inhibiteur des tyrosines kinases vegfr/fgfr/ret pour traiter le cancer
WO2016175305A1 (fr) *	2015-04-30	2016-11-03	大鵬薬品工業株式会社	Sel d'acide mésylique de composé d'acylthiourée, cristaux de lui-ci, et procédés pour le produire
CA2990791A1 (fr)	2015-06-25	2016-12-29	Taiho Pharmaceutical Co., Ltd.	Agent therapeutique contre la fibrose
JP6804832B2 (ja)	2015-07-21	2020-12-23	東芝ライフスタイル株式会社	冷蔵庫
CN106551911A (zh) *	2015-09-21	2017-04-05	天津市汉康医药生物技术有限公司	一种稳定的乐伐替尼药物组合物及其制备方法
EP3583943B1 (fr)	2017-02-15	2024-09-18	Taiho Pharmaceutical Co., Ltd.	Composition pharmaceutique

2018
- 2018-02-14 EP EP18755023.1A patent/EP3583943B1/fr active Active
- 2018-02-14 HU HUE18755023A patent/HUE068810T2/hu unknown
- 2018-02-14 ES ES18755023T patent/ES2991062T3/es active Active
- 2018-02-14 TW TW107105612A patent/TWI702951B/zh active
- 2018-02-14 FI FIEP18755023.1T patent/FI3583943T3/fi active
- 2018-02-14 KR KR1020217035697A patent/KR20210135354A/ko not_active Ceased
- 2018-02-14 JP JP2018568583A patent/JP6771594B2/ja active Active
- 2018-02-14 MX MX2019009717A patent/MX383728B/es unknown
- 2018-02-14 KR KR1020197023592A patent/KR102323255B1/ko active Active
- 2018-02-14 SG SG11201907433TA patent/SG11201907433TA/en unknown
- 2018-02-14 WO PCT/JP2018/005140 patent/WO2018151177A1/fr not_active Ceased
- 2018-02-14 PT PT187550231T patent/PT3583943T/pt unknown
- 2018-02-14 MY MYPI2019004652A patent/MY194278A/en unknown
- 2018-02-14 CA CA3053739A patent/CA3053739C/fr active Active
- 2018-02-14 CN CN201880012000.XA patent/CN110312511B/zh active Active
- 2018-02-14 AU AU2018222163A patent/AU2018222163C1/en active Active
- 2018-02-14 MA MA047516A patent/MA47516A/fr unknown
- 2018-02-14 DK DK18755023.1T patent/DK3583943T3/da active
- 2018-02-14 PL PL18755023.1T patent/PL3583943T3/pl unknown
- 2018-02-14 MX MX2021007061A patent/MX2021007061A/es unknown
- 2018-02-14 US US16/485,971 patent/US11110062B2/en active Active
- 2018-02-14 CN CN202311298292.7A patent/CN117137915A/zh active Pending
2019
- 2019-08-13 PH PH12019501873A patent/PH12019501873A1/en unknown
2021
- 2021-06-15 US US17/347,989 patent/US12144892B2/en active Active

Also Published As

Publication number	Publication date
KR20190113831A (ko)	2019-10-08
AU2018222163B2 (en)	2021-01-28
TW201836608A (zh)	2018-10-16
RU2019125612A (ru)	2021-03-16
CN117137915A (zh)	2023-12-01
MX2019009717A (es)	2019-10-02
EP3583943A4 (fr)	2020-12-30
DK3583943T3 (da)	2024-10-14
EP3583943B1 (fr)	2024-09-18
KR102323255B1 (ko)	2021-11-08
US11110062B2 (en)	2021-09-07
CN110312511B (zh)	2023-10-27
JP6771594B2 (ja)	2020-10-21
MX383728B (es)	2025-03-14
CA3053739A1 (fr)	2018-08-23
HUE068810T2 (hu)	2025-01-28
CA3053739C (fr)	2023-02-14
RU2019125612A3 (fr)	2021-03-16
AU2018222163C1 (en)	2021-08-12
PL3583943T3 (pl)	2024-11-25
US12144892B2 (en)	2024-11-19
PT3583943T (pt)	2024-10-15
KR20210135354A (ko)	2021-11-12
MY194278A (en)	2022-11-25
EP3583943A1 (fr)	2019-12-25
AU2018222163A1 (en)	2019-09-05
CN110312511A (zh)	2019-10-08
US20210308056A1 (en)	2021-10-07
BR112019016764A2 (pt)	2020-03-31
TWI702951B (zh)	2020-09-01
US20200060973A1 (en)	2020-02-27
FI3583943T3 (fi)	2024-10-29
PH12019501873A1 (en)	2020-06-15
JPWO2018151177A1 (ja)	2019-11-07
MA47516A (fr)	2021-03-31
WO2018151177A1 (fr)	2018-08-23
MX2021007061A (es)	2022-10-07
SG11201907433TA (en)	2019-09-27

Publication	Publication Date	Title
ES2991062T3 (es)	2024-12-02	Composición farmacéutica
JP5048871B2 (ja)	2012-10-17	キノリン誘導体含有医薬組成物
NZ502990A (en)	2002-02-01	Pharmaceutical compositions of meloxicam with improved solubility and bioavailability
ES2930663T3 (es)	2022-12-20	Formulación oral solida que contiene irinotecán y método para preparar la misma
ES2940306T3 (es)	2023-05-05	Composición farmacéutica estable para administración oral
JP6582000B2 (ja)	2019-09-25	エンテカビルを有効成分として含む薬学製剤及びこの製造方法
WO2015152680A1 (fr)	2015-10-08	Granulé comprenant de la silodosine, composition et formulation pharmaceutiques comprenant ce granulé
JP7378279B2 (ja)	2023-11-13	ニロチニブを有効成分とする医薬錠剤及びその製造方法
RU2772939C2 (ru)	2022-05-27	Фармацевтическая композиция
JP7267290B2 (ja)	2023-05-01	経口ベンダムスチン製剤
JP2020176107A (ja)	2020-10-29	吸湿性成分を含むコーティング錠
BR112019016764B1 (pt)	2025-02-11	Composição farmacêutica contendo 4- (2-fluoro-4- (3-(2-fenilacetil) tioureído) fenóxi) - 7-metóxi-nmetilquinolina-6-carboxamida ou um sal armaceuticamente aceitável do mesmo e um derivado de ciclodextrina, e seu método de produção
JP7023600B2 (ja)	2022-02-22	シロドシン含有医薬組成物とその製造方法
HK40014596A (en)	2020-08-21	Pharmaceutical composition
WO1989006959A1 (fr)	1989-08-10	Preparation pharmaceutique a liberation amelioree
WO2023238929A1 (fr)	2023-12-14	Composition pharmaceutique contenant du pimitespib
Tomás	2019	Hydrochlorothiazide Tablets formulated in a Ternary system with Cyclodextrin and Nanoclay
JP2004250443A (ja)	2004-09-09	固形製剤
TW202034914A (zh)	2020-10-01	口服苯達莫司汀製劑
TW201233673A (en)	2012-08-16	Pharmaceutical composition comprising quinoline derivative